145 related articles for article (PubMed ID: 24902539)
1. Phenoxodiol enhances the antitumor activity of gemcitabine in gallbladder cancer through suppressing Akt/mTOR pathway.
Li Y; Huang X; Huang Z; Feng J
Cell Biochem Biophys; 2014 Nov; 70(2):1337-42. PubMed ID: 24902539
[TBL] [Abstract][Full Text] [Related]
2. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.
Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK
Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590
[TBL] [Abstract][Full Text] [Related]
3. Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-κB.
Zhang DC; Liu JL; Ding YB; Xia JG; Chen GY
Acta Pharmacol Sin; 2013 Feb; 34(2):301-8. PubMed ID: 23274410
[TBL] [Abstract][Full Text] [Related]
4. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
Cui J; Guo Y; Wu H; Xiong J; Peng T
Mol Med; 2021 Apr; 27(1):38. PubMed ID: 33849427
[TBL] [Abstract][Full Text] [Related]
5. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.
Zhang P; Guo Z; Wu Y; Hu R; Du J; He X; Jiao X; Zhu X
PLoS One; 2015; 10(8):e0136193. PubMed ID: 26287365
[TBL] [Abstract][Full Text] [Related]
7. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.
Mu GG; Zhang LL; Li HY; Liao Y; Yu HG
Dig Dis Sci; 2015 Apr; 60(4):1067-80. PubMed ID: 25344906
[TBL] [Abstract][Full Text] [Related]
8. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
9. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
10. Melatonin inhibits proliferation, migration, and invasion by inducing ROS-mediated apoptosis via suppression of the PI3K/Akt/mTOR signaling pathway in gallbladder cancer cells.
Chen K; Zhu P; Chen W; Luo K; Shi XJ; Zhai W
Aging (Albany NY); 2021 Sep; 13(18):22502-22515. PubMed ID: 34580235
[TBL] [Abstract][Full Text] [Related]
11. The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
Song J; Xu J; Guo J; Shang Y; Wang J; Wang T
Acta Histochem; 2021 Sep; 123(6):151769. PubMed ID: 34416437
[TBL] [Abstract][Full Text] [Related]
12. Liensinine induces gallbladder cancer apoptosis and G2/M arrest by inhibiting ZFX-induced PI3K/AKT pathway.
Shen Y; Bian R; Li Y; Gao Y; Liu Y; Xu Y; Song X; Zhang Y
Acta Biochim Biophys Sin (Shanghai); 2019 Jun; 51(6):607-614. PubMed ID: 31074773
[TBL] [Abstract][Full Text] [Related]
13. The O-methylated isoflavone, formononetin, inhibits human ovarian cancer cell proliferation by sub G0/G1 cell phase arrest through PI3K/AKT and ERK1/2 inactivation.
Park S; Bazer FW; Lim W; Song G
J Cell Biochem; 2018 Sep; 119(9):7377-7387. PubMed ID: 29761845
[TBL] [Abstract][Full Text] [Related]
14. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system.
Yu WD; Ma Y; Flynn G; Muindi JR; Kong RX; Trump DL; Johnson CS
Cell Cycle; 2010 Aug; 9(15):3022-9. PubMed ID: 20699664
[TBL] [Abstract][Full Text] [Related]
15. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
[TBL] [Abstract][Full Text] [Related]
16. Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines.
Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Palmeira C; Colaço A; Moreira da Silva V; Oliveira P; Lara Santos L
Urol Oncol; 2014 Jan; 32(1):41.e11-22. PubMed ID: 24035472
[TBL] [Abstract][Full Text] [Related]
17. sMEK1 enhances gemcitabine anti-cancer activity through inhibition of phosphorylation of Akt/mTOR.
Byun HJ; Kim BR; Yoo R; Park SY; Rho SB
Apoptosis; 2012 Oct; 17(10):1095-103. PubMed ID: 22903553
[TBL] [Abstract][Full Text] [Related]
18. α-Mangostin suppresses the de novo lipogenesis and enhances the chemotherapeutic response to gemcitabine in gallbladder carcinoma cells via targeting the AMPK/SREBP1 cascades.
Shi Y; Fan Y; Hu Y; Jing J; Wang C; Wu Y; Geng Q; Dong X; Li E; Dong D
J Cell Mol Med; 2020 Jan; 24(1):760-771. PubMed ID: 31762191
[TBL] [Abstract][Full Text] [Related]
19. BLU enhances the effects of anti-angiogenic activity in combination with gemcitabine-based chemotherapeutic agents.
Yoo HJ; Kim BR; Byun HJ; Park SY; Rho SB
Int J Biochem Cell Biol; 2013 Jul; 45(7):1236-45. PubMed ID: 23579097
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells.
Alvero AB; O'Malley D; Brown D; Kelly G; Garg M; Chen W; Rutherford T; Mor G
Cancer; 2006 Feb; 106(3):599-608. PubMed ID: 16388521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
